Egnyte Creates Egnyte for Life Sciences Platform
Egnyte has announced Egnyte for Life Sciences, a purpose-built platform to serve those advancing the science of health. Egnyte’s solution aims to help biotech, medical device, and diagnostics companies accomplish three outcomes: meeting regulatory compliance standards, expedite data sharing and collaboration, and secure essential intellectual property.
The platform provides document management capabilities to facilitate intra- and inter-institutional collaboration while maintaining compliance with FDA 21 CFR Part 11 directives.
Egnyte is also announcing the formation of a Life Sciences Advisory Board to shape its offerings and go-to-market strategy in the industry.
Read the full release,
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025